Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): September 25,
2017
INNOVUS PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-52991
|
90-0814124
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS
Employer Identification No.)
|
|
9171 Towne Centre
Drive, Suite 440, San Diego, CA
|
|
92122
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 964-5123
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17
CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR
240.13e-4(c))
|
In this
report, “Innovus Pharmaceuticals,” “Innovus
Pharma,” “the Company”, “we,”
“us” and “our” refer to Innovus
Pharmaceuticals, Inc., and/or one or more of our wholly-owned
subsidiaries, unless the context otherwise provides. Innovus
Pharma® is a registered service mark of Innovus
Pharmaceuticals, Inc.
Item 8.01 – Other Events
On September 26, 2017, the Company issued a press release
announcing the availability of the full label for its nasal drug
FlutiCare™ (NDC: 57483-005-02) for allergy symptom relief on the U.S. Food and
Drug Administration’s public drug disclosure database,
DailyMed. DailyMed is the on-line database that all new drugs are
described on that provides information to the public on its
ingredients and usage. The DailyMed description is available
through the site below:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c72952e6-bfe5-485b-8c62-787ff4179b62
The
full text of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K.
Item 9.01 -- Financial Statements and Exhibits
(d) Exhibits
|
Exhibit Number
|
Description
|
|
|
Press
release issued September 27, 2017.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Date:
September 27, 2017 |
INNOVUS
PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
|
By:
|
/s/
Bassam
Damaj
|
|
|
|
|
Bassam
Damaj |
|
|
|
|
President and Chief
Executive Officer
|
|
EXHIBIT
INDEX
|
Exhibit Number
|
Description
|
|
|
Press
release issued September 27, 2017.
|